

2022/2023


Financial Report



*Aboriginal Respect
Symbol. Designed by
Marcus Lee Design for
Cancer Council NSW.*

Cancer Council NSW would like to acknowledge the Traditional Custodians of the land on which we live and work.

We would also like to pay respect to the Elders past, present and emerging, and extend that respect to all other Aboriginal and Torres Strait Islander peoples.



Get involved

Cancer Council is standing by everyone living with cancer, protecting life's moments, for life. This is only possible thanks to the incredible generosity of our volunteers, supporters and employees. Together, we work across every area of cancer, supporting communities where and when it's most needed.

With the help of our supporters, we are leading the way towards a cancer free future.

There are many ways you can get involved with us and help change the lives of people affected by cancer.

- Volunteer with us
- Give regularly
- Host or join a fundraising event
- Campaign with us
- Visit one of our retail stores

To find out more, visit cancercouncil.com.au/get-involved

Contents

2022/23 Highlights	4
Our performance over time	6
Where the money comes from	8
How we put the money to work	9
Directors' report	10
Auditor's declaration of independence	16
Statement of profit or loss and other comprehensive income	17
Statement of financial position	18
Statement of changes in equity	19
Statement of cash flows	20
Notes to the financial statements	21
Directors' declaration	32
Declaration by Chief Executive Officer in respect of fundraising appeals	33
Independent auditor's report	34



This free and confidential service is staffed by experienced cancer professionals, who provide evidence-based information and support to people affected by cancer.

2022/23 Highlights

To all of the volunteers, fundraisers, donors and partners in the Cancer Council NSW community, thank you. With your continued support, we're able to stand by everyone impacted by cancer, protecting life's moments, for life.

In 2023, we made significant strides towards making a generational impact on cancer – harnessing world-class research to save lives and help people reduce their cancer risk.

We transformed our processes, meaning we are now supporting people affected by cancer more efficiently and effectively than ever before.

And we delivered new resources to improve cancer outcomes for communities who need it most.

Read on to learn more about the impact you enabled in 2023. Once again, thank you.

Here is a snapshot of what our supporters helped achieve in 2022/23:



INCREASING CANCER SURVIVAL

In 2022/23, we invested **\$18.2 million** in world-class research:

235
researchers

58
projects

27
institutions

In 2022/23, we awarded funding for **12 ground-breaking projects** paving the way for new and more effective cancer treatments. These included projects leveraging stem-like memory T cells for effective anti-cancer mRNA vaccines; developing personalised treatments for pancreatic cancer; and designing a targeted treatment for aggressive lung cancer.

For the past decade, Cancer Council NSW researchers (now part of the Daffodil Centre*) have led and partnered on crucial research into the feasibility of lung cancer screening in Australia. In 2022, cutting-edge independent economic analysis published by the Daffodil Centre showed that lung cancer screening in Australian health settings would be effective and cost-effective. The study was pivotal to Australia's independent Medical Services Advisory Committee's support for the introduction of a lung cancer screening program, announced in July 2022. The Australian Minister for Health and Aged Care, Mark Butler, followed up in the 2023 federal budget, announcing the program's introduction from July 2025 – a landmark event in cancer control in Australia, informed by independent Daffodil Centre research.

*The Daffodil Centre is a joint venture between Cancer Council NSW and the University of Sydney.



IMPROVING THE QUALITY OF LIFE OF PEOPLE AFFECTED BY CANCER

3,464 people who were struggling with the high cost of cancer received **\$1,154,258** worth of financial assistance payments. Due to the increasing cost of living, we supported 22% more people in 2022/23 compared to 2021/22 and provided 18% more financial assistance in real dollar terms.

Our **13 11 20** Information and Support team received **9,074 calls and emails** from people affected by cancer, health professionals and the general public.

Our Transport to Treatment drivers made **19,847 trips**, so cancer patients and carers could get to life-saving treatment.

We provided **14,016 nights** of affordable accommodation to cancer patients and carers, so they could stay close to their treatment centres.



REDUCING CANCER RISK

We have led on Australian first research into vaping with our **Generation Vape research project** (in collaboration with the Daffodil Centre and the University of Sydney, with funding from the Australian Government Department of Health, the NSW Ministry of Health, Cancer Institute NSW and Minderoo Foundation). Our research directly informed the Australian Government's May 2023 announcement of decisive new action on vaping, to safeguard our tobacco control successes, stop a new generation from becoming addicted to nicotine and prevent young people taking up smoking. The findings from Generation Vape have also directly informed the NSW Department of Education's updated curriculum on vaping and smoking for secondary school students.

231 golf clubs participated in **Improve your long game** in 2022/23, protecting golfers from harmful UV radiation exposure.

People were inspired to create healthy recipes for the whole family by visiting the **Healthy Lunch Box** website **252,081 times**.



IMPROVING CANCER OUTCOMES FOR PRIORITY POPULATIONS

Throughout 2022/23, our community-facing teams held **96 community events** across NSW to improve understanding and access to bowel, breast and cervical screening, reaching over **9,900 people**.

As part of our **Here for Change** advocacy campaign ahead of the NSW state election, we called on the NSW government to increase investment in cancer prevention, improve early detection and diagnosis of bowel and other cancers, introduce fairer access to cancer care and support people to live well during and after a cancer diagnosis:

- We held **176** Member of Parliament (MP) engagement activities across NSW.
 - We engaged over **60%** of all (57) MPs.
 - We motivated **58** acts of support from MPs (e.g. letters to ministers, sharing on social media, media)
 - Almost **5,000** community members signed our petition.
-

We launched our **re-designed Aboriginal web portal** in May 2023, to help support Aboriginal and Torres Strait Islander people, who we know experience higher rates of cancer diagnosis and mortality than the Australian population overall. To update the portal, we consulted extensively with community, worked with Ngakkan Nyaagu (NGNY), the APOCC Research Project Advisory Group, and Aboriginal artists and designers. In its first months, the new portal received **25% more visits** from community compared to the previous year.

In collaboration with Western Sydney University's Out with Cancer research project, we launched a **dedicated cancer information resource for LGBTQI+** people, their families and friends in February 2023. This new resource was designed to address the specific needs of LGBTQI+ people, who we know experience higher levels of distress during cancer treatment and poorer cancer outcomes. By the end of June, people visited the new web page **10,959** times, downloaded the new booklet **765** times and picked up **601** print copies across NSW.

Our performance over time

Our investment in research

This year we enabled **\$18.2m of world-class cancer research** through both the Daffodil Centre and continued funding of external research projects.

Total research expenditure*		Total research grants funded
\$19.0m	2019	65
\$19.8m	2020	67
\$16.8m**	2021	67
\$18.3m	2022	57
\$18.2m	2023	55

*Includes research we fund and conduct.

**The reduction in research expenditure in 2021 mostly reflects COVID-related deferrals of grant payments and a tail-off in payments for some older grant types.

We also partnered with government and collaborators, seeking competitive grant and contract funding.



	2019	2020	2021	2022	2023
Number of research grants received	21	19	31	28	42
Total research income (\$m)	2.3	2.3	4.4	4.3	4.9

Raising funds towards a cancer free future

We are so grateful to our generous supporters who continue to fundraise and donate to us this year, while we all faced added financial pressure from rising interest rates and inflation.



	2019	2020	2021	2022	2023
Total fundraising income (\$m)	63.8	48.1	58.9	53.8	66.2
Number of people who left us a Gift in their Will	147	134	131	78	106*

*We are grateful for the generosity of the 106 people who left a gift in their will this year. These incredible legacies will make a difference to the future of cancer.

Reducing cancer risk

We are working to prevent cancer by creating healthier environments and empowering people to reduce their cancer risk.

Percentage of primary schools participating in our SunSmart program



2019	2020	2021	2022	2023
80%	82%	84%	84%	86%

Number of golf clubs participating in *Improve your long game**



2019	2020	2021	2022	2023
108	183	198	205	231

* *Improve your long game* is our free sun protection program in NSW golf clubs. In NSW, men over the age of 40 are 1.5 more likely to be diagnosed with melanoma and 2.5 times more likely to die from melanoma than women of the same age. *Improve your long game* has proven successful at engaging this often difficult to reach group.

Supporting people with cancer

CCNSW's incredible volunteers and staff members ensured cancer patients had access to the supportive care they needed.

Number of trips by our Transport to Treatment service



2019	2020	2021	2022	2023
28,407	19,070*	20,833	18,620	19,847

*From 2020 onwards, we've seen lower numbers of Transport to Treatment trips due to the COVID-19 pandemic, which forced the temporary closure of some services and introduced capacity limits. We hope to see trip volumes increase to pre-pandemic levels in the coming years. To support this, in 2023 we introduced a new way of delivering the service, where possible working closely with other community transport providers, to support clients and ensure we are reaching the people in the most need.

Number of accommodation nights



2019	2020	2021	2022	2023
23,144	23,816	17,797*	13,276*	14,016*

*The reduction in the number of accommodation nights reflects a change in the way we measure and report on data for this service since 2022, as well as the ongoing implications of COVID-19 reducing the total number of people receiving treatment. We are slowly seeing an increase in room nights as people resume cancer screenings, and diagnosis and treatment services following the disruptions of the pandemic.

Financial assistance payments (\$)



2019	2020	2021	2022	2023
1,013,258	1,021,325	1,020,805	977,700	1,154,258*

*We saw an increase in clients requesting Financial Assistance, due to increasing cost of living, which is having a significant impact on people with cancer in financial hardship in NSW.

Individual listens of our cancer support and information podcasts



2019	2020	2021	2022	2023
13,194	23,243*	17,939*	29,956*	40,233*

*We saw a large spike in listens in 2020 due to a new series launch and associated promotion resulting in an overall drop for 2021. In 2022 and 2023, listens spiked again due to the launch of an additional Cancer Council podcast series called Finding Calm During Cancer and improvements made to website functionality.

Understanding Cancer books and fact sheets distributed in print and digital formats



2019	2020	2021	2022	2023
179,813	146,878	119,481*	143,303*	200,115

*We distributed fewer *Understanding Cancer* resources in hospitals, treatment centres and local offices in these years due to disruptions from the COVID-19 pandemic.

Number of legal, financial and workplace issues




2019	2020	2021	2022	2023
4,003	3,508	2,942*	2,646*	2,818

*We saw referrals to our professional volunteers decrease in 2021 and 2022 due to COVID-19, as clients did not attend treatment centres as often for referrals to health professionals. In 2023, we witnessed a gradual increase in clients accessing free legal, financial, small business accounting and workplace assistance, as people resume cancer screenings and diagnosis and treatment services following the disruptions of the pandemic, coupled with rising costs of living.



Thanks to our community's support, we are here to help everyone affected by cancer when they need it most.


Where the money comes from



	2019		2020		2021		2022		2023	
	\$m	%	\$m	%	\$m	%	\$m	%	\$m	%
Gifts in Wills	17.5		9.6		20.7		14.0		18.7	
Regular giving, appeals and donations	20.9		19.8		18.6		18.1		18.7	
Campaigns	22.5		15.1		16.3		13.2		17.2	
Philanthropy	2.9		3.6		2.7		8.5		11.6	
Total fundraising	63.8	78%	48.1	72%	58.3	72%	53.8	69%	66.2	74%
Sale of sun protection products (retail)	7.6	10%	5.8	9%	5.2	6%	5.2	7%	6.6	7%
Investments	5.1	6%	4.0	6%	6.0	8%	11.1	14%	7.0	8%
Grants	3.4	4%	6.9	10%	10.6	13%	6.8	9%	6.6	7%
Donations-in-kind income									2.1	2%
Other income	1.7	2%	1.8	3%	1.1	1%	1.0	1%	1.4	2%
Total income*	81.6		66.6		81.2		77.9		89.9	

*Excludes capital gains on investments.

How we put the money to work



	2019		2020		2021		2022		2023	
Mission expenditure	\$m	%	\$m	%	\$m	%	\$m	%	\$m	%
Research	19.0		19.8		16.8		18.2		18.2	
Advocacy and cancer prevention	7.7		7.4		6.9		8.4		10.1	
Cancer information and support	17.5		15.3		14.4		15.4		16.4	
Sale of sun protection products (retail)	7.2		5.9		4.9		5.0		5.8	
Direct mission support	0.8		1.7		1.5		2.4		2.3	
Total mission*	52.2	64%	50.1	66%	44.5	65%	49.4	66%	52.8	62%
Mission enabling expenditure	\$m	%	\$m	%	\$m	%	\$m	%	\$m	%
Fundraising	26.0	32%	23.4	31%	21.7	31%	23.1	31%	27.7	32%
Administration**	3.5	4%	2.7	3%	2.4	4%	2.1	3%	2.9	4%
Donations-in-kind expense									1.9	2%
Total expenditure***	81.7		76.2		68.6		74.6		85.3	

*Mission expenditure returned to pre-pandemic levels in 2023 but the mission ratio declined, mainly due to increased fundraising activity and resulting expenditure.

**Items from these categories which are directly related to mission have been reallocated to direct mission support.

***Excludes capital losses on investments.

Directors' report

For the year ended 30 June 2023

The Directors of Cancer Council NSW (CCNSW) present their report with respect to the results for the financial year ended 30 June 2023 and the state of CCNSW's affairs at that date.

Board of Directors

CCNSW's Constitution provides that the Board directs the affairs of CCNSW. In carrying out its responsibilities and exercising its powers, the Board recognises its overriding responsibility to act honestly, fairly and diligently, and in accordance with the law in serving the interests of CCNSW, including its members, volunteers, supporters, employees and the community.

The following persons were Directors of CCNSW at any time during or since the end of the financial year:

- Nicholas Adams
- Michael Barton
- James Butler
- Nerida Dean
- Haryana Dhillon
- Peeyush Gupta
- Carolyn Heise
- John Laker (Chair)
- Jo Mitchell
- Michael Morgan

About Cancer Council NSW

CCNSW is a member of a national federation of Cancer Councils that covers every state and territory across Australia. Cancer Council believes in a cancer free future and is the only charity in Australia that works across every cancer. While collaborating nationally on issues that impact all Australians, together with its volunteers, supporters, stakeholders, and employees, CCNSW is focused on opportunities, needs and initiatives of importance to NSW.

As the largest cancer charity in Australia, CCNSW is committed to reducing the impact of cancer by reducing cancer risk, increasing cancer survival, improving the quality of life for people affected by cancer, and improving cancer outcomes.

Principal activities during the year and how they assisted in achieving our objectives

The principal activities of CCNSW during the year were aimed at achieving its short and long-term outcomes in the following focus areas:

- research
- prevention
- information and support
- advocacy
- fundraising
- working with the NSW community, and
- our people

We provide more detail on our activities and achievements in the financial year on pages 4-7 in this document.

How we measure performance

We assess the outcome of our work in relation to:

- the prevalence of adverse cancer risks and healthy behaviours
- the unmet needs of cancer patients
- the support of community and government leaders for our agenda in cancer control
- the quality and impact of results from research, and
- trends in net returns from revenue programs.

Key performance indicators

The operational effectiveness of our work is measured by:

- the coverage of target populations or settings with programs in cancer prevention and support
- mission expenditure ratios to ensure expenditure on mission delivery is maximised
- net income from fundraising and revenue streams
- fundraising cost to income ratios
- the number of NSW people engaged as donors, volunteers, advocates and research participants, and
- the match between the distribution of research funding and the burden of disease and cancer in NSW.

Our key performance indicators and our results for the past five years are outlined in pages 6–7 of this document. Data is captured and reported regularly to provide insight into performance and outcomes. CCNSW conducts regular business reviews and uses its internal auditors to review and advise on the performance of various programs and to identify opportunities for improvements. Annual performance planning is conducted for all staff to ensure alignment with the organisation's direction.

Information on our Directors

Nicholas Adams

BCom (Marketing)

*Chair of the Fundraising and Marketing Committee,
Member of the IT Steering Committee*

Elected to the Board in December 2015, re-elected in December 2018, and re-elected in December 2021.

Mr Adams is a leading Australian marketer and has 24 years' experience in financial services and telecommunications marketing with companies such as Allianz, Telstra, Westpac, and American Express.

As a marketing leader, he has expertise in customer relationship management (CRM), loyalty and digital marketing, and building data-driven marketing programs to drive both revenue and customer engagement with brands.

Emeritus Professor Michael Barton OAM

MBBS, MD, FRANZCR

Member of the Cancer Research Committee

Appointed to the Board in April 2021.

Emeritus Professor Barton OAM is Professor of Radiation Oncology at UNSW Sydney. He has research interests in Health Services research and is a global leader in the benchmarking of cancer services. He was part of the leadership of the team developing one of the world's first MRI-guided linear accelerators. Professor Barton has worked for International Atomic Energy Agency on radiotherapy projects in Africa, Asia, and Latin America. Professor Barton chaired the National Adult Glioma Guidelines. He has a long track record of working with consumers on the design, execution and publication of research projects including the Ideal Curriculum in Oncology for Medical Students, publications in Lancet Oncology and the Medical Journal of Australia.

In 2007 he was awarded the Medal of the Order of Australia, for service to medicine, particularly radiation oncology, through a range of clinical, research, education, and professional development roles. In 2021 he received the Clinical Oncology Society of Australia Tom Reeve Award for Outstanding Contributions to Cancer Care.

James Butler OAM

Member of the Remuneration and Nomination Committee, Chair of the Consumer Research Review Panel, former Chair of the Relay For Life Steering Committee, Co-Chair of the Aboriginal Advisory Committee

Elected to the Board in December 2014, re-elected in December 2017, and re-elected in December 2020.

Mr Butler has been an active volunteer for Cancer Council NSW for 25 years, holding roles including Chair of the Hills Relay For Life Committee, and Chair of the Western Sydney Cancer Advocacy Network. He is a trained Cancer Council NSW advocate. As a two-time cancer survivor, he understands the need to influence decision-makers around key issues that have an impact on people affected by cancer.

Mr Butler is currently Chair of Cancer Council NSW's Consumer Research Review Panel. Mr Butler has also been a business owner for 25 years (now retired) and is an active consumer representative on cancer services committees in the Western Sydney Local Health District. Mr Butler was awarded a Medal of the Order of Australia in June 2022 for his service to people with cancer and his dedication to the work of Cancer Council NSW.

.

A/Professor Haryana Dhillon

BSc MA(Psych) PhD

Member of the Governance Committee, Member of the Cancer Research Committee

Appointed to the Board in July 2019 and resigned in August 2023.

A/Professor Dhillon (BSc MA PhD) is an Associate Professor in Psycho-Oncology at the University of Sydney. She is a Director of the Centre for Medical Psychology & Evidence-based Decision-making, and a Research Fellow, Science in the School of Psychology at the University of Sydney where she co-leads the Cancer Survivorship Research Group.

A/Professor Dhillon has more than 25 years' experience in cancer clinical research originally working with the NHMRC Clinical Trial Centre, the University of Sydney across a range of investigator-initiated cancer clinical trials. Over the past 15 years she has focused more on psycho-oncology and behavioural research.

A/Professor Dhillon was formerly a member of the Clinical Oncology Society of Australia Board and Chair of the Survivorship group of COSA. She is Chair of the Scientific Advisory Committee of the Psycho-Oncology Cooperative Research.

Nerida Dean

BEd Dip Ed (UNE)

Member of the Remuneration and Nomination Committee, Member of the Fundraising and Marketing Committee

Appointed to the Board in October 2018, then elected to the Board in December 2018 and re-elected in December 2021.

Ms Dean brings a wealth of experience and a strong community perspective. She has spent the bulk of her working life as a secondary teacher and has served on several Boards at a local and regional level, including as the Deputy Chair Queanbeyan Local Health Committee for 14 years.

Ms Dean is currently a member of the Rotary Club of Mullumbimby and is involved with the build of the new Tweed Hospital. She has been involved with Cancer Council NSW for eight years, taking on numerous volunteer roles such as Community Speaker, MP Liaison, Relay for Life Committee member, Eat It To Beat It facilitator, Australia's Biggest morning tea host and Daffodil Day stall holder.

Peeyush Gupta AM

MBA (Finance)

Member of the Investment Committee and IT Steering Committee

Appointed to the Board in August 2022.

Mr Gupta AM is the Chairman and non-executive Director on a range of commercial, public sector and not-for-profit boards, including as Chair of Charter Hall Long Wale REIT and Charter Hall Direct Property Management Ltd, and as a Director of National Australia Bank, Special Broadcasting Service (SBS), Link Administration, Quintessence Labs, and Northern Territory Aboriginal Investment Corporation. This includes serving on various sub-Committees of these Boards including in risk, audit, remuneration, and investment. Mr Gupta was the co-founder and inaugural CEO of IPAC Securities, a wealth management firm providing financial advice and institutional portfolio management in Australia and internationally.

Mr Gupta holds a Master of Business Administration in Finance from the Australian Graduate School of

Management, University of NSW, and is also an alumnus of Harvard and the London Business School. He was awarded a Member of the Order of Australia (AM) in January 2019 for significant service to business and the community through governance and philanthropic roles.

Carolyn Heise**BN, RN, PGDip Public Health (Leadership), MBA***Chair of the Remuneration and Nomination Committee,
Member of the Aboriginal Advisory Committee*

Elected to the Board in December 2020.

Ms Heise is a dedicated registered nurse and health service leader. She is passionate about the nursing profession and the provision of high-quality health services to her community. Ms Heise is currently the District Director of Nursing and Midwifery, for the Mid North Coast Local Health District. Ms Heise's dynamic and varied career has included working as a registered nurse, managing district cancer services, public hospitals, and preventative health care services on the Mid North Coast of NSW. She holds additional post-graduate qualifications in Public Health and a Master of Business Administration.

Ms Heise has worked alongside Cancer Council in Regional NSW for many years and while in the Position of Nurse Manager for the Mid North Coast Cancer Institute in 2017, she actively participated in fundraising events such as Australia's Biggest Morning Tea and as a contestant in Coffs Coast Dancing with the Stars.

In 2019 while working as the Director of Nursing, Midwifery and In-Patient Services at Coffs Harbour Base Hospital, Ms Heise was diagnosed with cancer. As such, she has a unique perspective on the patient journey – both as a senior health service manager and as a survivor of cancer.

Dr John Laker AO**BEd (Hons 1) (Syd), MSc (Econ) PhD (London), HonDSc (Syd)***Chair of the Board from 8 December 2021. Chair of the Governance Committee and Cancer Council NSW representative on the Cancer Council Australia Board*

Elected to the Board in December 2014, re-elected in December 2017, and re-elected in December 2020.

Dr Laker was Chairman of the Australian Prudential Regulation Authority (APRA), the regulator of the Australian financial services industry, from 2003 to 2014. An economist by training, Dr Laker had an extensive career in the Reserve Bank of Australia, both in Australia and London, before his appointment to APRA. He has also worked in the Commonwealth Treasury and the International Monetary Fund (IMF).

Currently, Dr Laker is Chairman of ING Bank Australia and Deputy Chancellor and member of the Council of the University of Technology Sydney. He is a member of the Consultative Panel of the Australian Securities and Investments Commission (ASIC) and an External Expert for the IMF, participating in a number of reviews of major banking systems. Dr Laker was made an Officer of the Order of Australia in 2008 and has won other professional awards for his services to the regulation of the Australian financial system.

Dr Jo Mitchell PSM**BSc, Post Grad Dip Nut & Diet, MPH, DrPH, GAICD***Member of the Audit and Risk Committee, Member of the Remuneration and Nomination Committee, Cancer Council NSW representative on the Cancer Council Australia Board*

Appointed to the Board in November 2019.

Dr Mitchell has worked in preventive health for more than 30 years. Her career has included senior public sector executive experience, most recently as policy lead for population health in NSW. This portfolio covered a range of complex and contested policy issues including drug and alcohol, HIV, and sexually transmitted infections, overweight and obesity, tobacco control and viral hepatitis.

In 2018 Dr Mitchell was awarded the Public Service Medal for her contribution to population health policy in NSW.

She is currently an independent consultant and senior advisor to The Australian Prevention Partnership Centre. Dr Mitchell has degrees in science, nutrition, and public health.

Michael Morgan**BSc (Arch) BArch FRAIA***Chair of the Investment Committee, Chair of the Audit and Risk Committee from 1 May 2022, Member of the Fundraising and Marketing Committee*

Appointed to the Board in November 2020 and then elected in December 2020.

Mr Morgan is a registered architect, a Fellow of the Australian Institute of Architects and a director of nettletontribe where he has worked since 1979. He served as Managing Director for 26 years until commencing a leadership transition process in 2016.

Mr Morgan has been a member of the POSH Committee and an active supporter of Cancer Council NSW since 2003 and is the current Chair of the POSH Committee, a position he took up in late 2018.

He is also the Chairman of the Board of St Aloysius' College Ltd, Chairman of the Advisory Board for MacKillop Grange Retirement Village and a Director of Catholic Healthcare Ltd.

Directors' benefit

No Director of Cancer Council NSW has received, or has become entitled to receive, a benefit in respect of their role as a Director.

Board and committee meeting attendance

	Full meetings of Directors		Aboriginal Advisory Committee		Audit and Risk Committee		Fundraising and Marketing Committee		Governance Committee		Investment Committee		IT Steering Committee		Remuneration and Nomination Committee		Cancer Research Committee	
	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B	A	B
N Adams	7	7	*	*	*	*	3	6	*	*	*	*	4	4	*	*	*	*
M Barton	7	7	*	*	*	*	*	*	*	*	*	*	*	*	*	*	3	3
J Butler	6	7	4	4	*	*	*	*	*	*	*	*	*	*	4	4	*	*
N Dean	7	7	*	*	*	*	6	6	*	*	*	*	*	*	4	4	*	*
H Dhillon	7	7	*	*	*	*	*	*	3	3	*	*	*	*	*	*	1	3
P Gupta¹	3	6	*	*	*	*	*	*	*	*	2	4	0	3	*	*	*	*
C Heise	6	7	2	4	*	*	*	*	*	*	*	*	*	*	4	4	*	*
J Laker	7	7	*	*	*	*	*	*	3	3	*	*	*	*	*	*	*	*
J Mitchell	6	7			5	6											*	*
M Morgan	6	7	*	*	6	6	5	6	*	*	5	5	*	*	*	*	*	*

A = Number of meetings attended.

B = Number of meetings held during the time the Director held office or was a member of the Committee during the year.

* = Not a member of the relevant Committee.

1 = Peeyush Gupta appointed 6 August 2022.

Review of financial operations and results

The results of CCNSW's operations in the financial year is a surplus of \$4,615,000 (2022: deficit of \$11,892,000). Fundraising income (excluding Gifts in Wills) of \$47,483,000 was 20% higher than the previous financial year, and 2% higher than pre-pandemic levels. Gifts in Wills revenue of \$18,703,000 is 15% higher than the five-year average. Distributions from our financial assets continue to deliver robust returns.

CCNSW continues to provide much-needed support to the NSW community impacted by cancer, and it is pleasing to see that this support grew in the current fiscal year.

Total equity at the beginning of the financial year was \$145.4m, and increased to \$150.0m by the end of the year.

This equity position, along with management's continued focus on growing income, give Directors confidence that CCNSW will be able to extend its support to the NSW community without impacting on the long-term financial stability of the organisation.

Members' liability

CCNSW is incorporated under the Corporations Act 2001 (Cth) and is a public company limited by guarantee. If CCNSW is wound up, its constitution states that each member of CCNSW is required to contribute a maximum of \$2 each towards meeting any liabilities of CCNSW. As at 30 June 2023 the number of members was 91 (2022: 94).



Dr John Laker AO

Director

Sydney

24 October 2023



Michael Morgan

Director

Sydney

24 October 2023

DECLARATION OF INDEPENDENCE BY LEAH RUSSELL TO THE DIRECTORS OF CANCER COUNCIL NSW

As lead auditor of Cancer Council NSW for the year ended 30 June 2023, I declare that, to the best of my knowledge and belief, there have been:

No contraventions of the auditor independence requirements of section 60-40 of the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and

No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Cancer Council NSW Name and the entities it controlled during the period.



Leah Russell
Director

BDO Audit Pty Ltd

Sydney

24 October 2023

Statement of profit or loss and other comprehensive income

For the year ended 30 June 2023

	Notes	2023 \$'000	2022 \$'000
Revenue and other income			
Fundraising	3, 4	66,186	53,761
Grants and government support	5	6,564	6,824
Interest and investment	4	6,964	11,036
Sale of sun protection products (retail)	4	6,654	5,191
Donations-in-kind income	4	2,134	-
Other income	4	1,410	1,034
Total revenue and other income	4	89,912	77,846
Expenses			
Fundraising	3	27,689	23,144
Research	3,6	18,172	18,240
Cancer information and support services	3	16,357	15,285
Advocacy and cancer prevention	3	10,173	8,374
Sale of sun protection products (retail)	3	5,826	5,044
Administration		2,912	2,126
Marketing and communications	3	2,310	2,363
Donations-in-kind expense	4	1,892	-
Total expenses		85,331	74,576
Operating surplus		4,581	3,270
Income tax expense	2 (c)	-	-
Increase / (decrease) in investments at fair value	9 (b)	34	(15,162)
Fair value adjustment to investment property		-	-
Surplus / (deficit) for the year		4,615	(11,892)
Other comprehensive income			
Items that will not be reclassified subsequently to surplus or deficit:			
Revaluation of land and buildings	11	-	1,118
Total other comprehensive income for the year		-	1,118
Net result for the year		4,615	(10,774)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Statement of financial position

As at 30 June 2023

	Notes	2023 \$'000	2022 \$'000
Assets			
Current assets			
Trade and other receivables	7	9,425	11,651
Cash and cash equivalents	8	12,047	8,632
Financial assets	9	12,424	21,218
Inventories		586	550
Total current assets		34,482	42,051
Non-current assets			
Financial assets	9	88,401	79,770
Property, plant and equipment	11	50,044	50,597
Intangible assets	12	2,629	5,447
Right of use assets	13	897	1,194
Total non-current assets		141,971	137,008
TOTAL ASSETS		176,453	179,059
Liabilities			
Current liabilities			
Trade and other payables	14	4,970	8,637
Provision for grants	15	7,094	7,374
Contract liabilities	10	2,537	3,878
Lease liabilities	16	412	929
Provisions - employee benefits	17	4,134	4,063
Total current liabilities		19,147	24,881
Non-current liabilities			
Provision for grants	15	5,925	7,446
Lease liabilities	16	488	318
Provisions - employee benefits	17	919	1,055
Total non-current liabilities		7,332	8,819
TOTAL LIABILITIES		26,479	33,700
NET ASSETS		149,974	145,359
Equity			
Accumulated funds		94,553	84,299
Asset revaluation reserve		46,309	46,309
Investments at fair value reserve		(454)	5,558
Restricted funds reserve		6,102	5,611
Grant income reserve		3,464	3,582
TOTAL EQUITY		149,974	145,359

The above statement of financial position should be read in conjunction with the accompanying notes.

Statement of changes in equity

For the year ended 30 June 2023

	Accumulated funds \$'000	Asset revaluation reserve \$'000	Investments at fair value reserve \$'000	Restricted funds reserve \$'000	Grant income reserve \$'000	Total equity \$'000
Opening balance as at 1 July 2021	83,488	45,191	20,720	4,262	2,472	156,133
Transfer to/(from) reserves	12,703	-	(15,162)	1,349	1,110	-
Deficit for the year	(11,892)	-	-	-	-	(11,892)
Other comprehensive income for the year	-	1,118	-	-	-	1,118
Net result for the year	(11,892)	1,118	-	-	-	(10,774)
Closing balance as at 30 June 2022	84,299	46,309	5,558	5,611	3,582	145,359
Opening balance as at 1 July 2022	84,299	46,309	5,558	5,611	3,582	145,359
Transfer to/(from) reserves	5,639	-	(6,012)	491	(118)	-
Surplus for the year	4,615	-	-	-	-	4,615
Other comprehensive income for the year	-	-	-	-	-	-
Net result for the year	4,615	-	-	-	-	4,615
Closing balance as at 30 June 2023	94,553	46,309	(454)	6,102	3,464	149,974

The above statement of changes in equity should be read in conjunction with the accompanying notes.

Nature and purpose of reserves

Accumulated funds

Accumulation of funds over time as a net result of past surpluses and deficits, including cumulative gain or loss from investment at fair value reserve on derecognition of investments.

Asset revaluation reserve

The asset revaluation reserve is used to record increments and decrements on the revaluation of CCNSW land and buildings, as described in Note 11.

Investments at fair value reserve

The investments at fair value reserve is used to record changes in the fair value of financial assets classified as investments at fair value through profit and loss, as described in Note 9(b).

Restricted funds reserve

The restricted funds reserve relates to bequests and donations received by CCNSW with a purpose specified in the bequest or by the donors. These funds are held in the restricted funds reserve until spent appropriately.

Grant income reserve

The grant income reserve relates to grant monies received but not yet spent. These funds are held in reserve until spent appropriately in line with the conditions of the funding agreement.

Statement of cash flows

For the year ended 30 June 2023

	2023 \$'000	2022 \$'000
Cash flows from operating activities		
Receipts from supporters and funding sources (inclusive of GST)	72,552	64,640
Receipts from grant and government funding	4,976	10,507
Dividends, franking credits and interest received	1,866	529
Payment for lease interest	(39)	(56)
Payments to suppliers and employees (inclusive of GST)	(82,690)	(75,206)
Net cash inflow/(outflow) from operating activities	(3,335)	414
Cash flows from investing activities		
Proceeds from sale of property, plant and equipment	62	87
Proceeds from sale of held for sale assets	-	1,176
Proceeds from sale of/(payment for) financial assets	8,860	(17,107)
Payments for purchase of intangible assets	(569)	(1,341)
Payments for purchase of property, plant and equipment	(675)	(544)
Net cash inflow/(outflow) from investing activities	7,678	(17,729)
Cash flows from financing activities		
Payments for principal portion of lease liabilities	(928)	(1,163)
Net cash outflow from financing activities	(928)	(1,163)
Net increase / (decrease) in cash and cash equivalents	3,415	(18,478)
Cash and cash equivalents at the beginning of the year	8,632	27,110
Cash and cash equivalents at end of year	12,047	8,632

The above statement of cash flows should be read in conjunction with the accompanying notes.

Notes to the financial statements

For the year ended 30 June 2023

1. Introduction

This financial report covers Cancer Council NSW (CCNSW) as an individual entity for the year ended 30 June 2023. The financial report is presented in Australian dollars, which is the company's functional and presentational currency.

CCNSW is a not-for-profit unlisted public company limited by guarantee, incorporated and domiciled in Australia. Its registered office and principal place of business is:

The Cancer Council NSW
153 Dowling Street
Woolloomooloo NSW 2011

A description of the nature of CCNSW's operations and its principal activities is included on page 10.

The financial report was authorised for issue by the Directors on 24 October 2023. The Directors have the power to amend and reissue this financial report.

2. Significant accounting policies

The principal accounting policies adopted in the preparation of this financial report are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

(a) Basis of preparation

These general-purpose financial statements have been prepared on a going concern basis and in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB), NSW legislation (the *Charitable Fundraising Act 1991* (NSW) and associated regulations), and the *Australian Charities and Not-for-profits Commission Act 2012* (Cth), as appropriate for not-for-profit oriented entities.

CCNSW has applied Simplified Disclosure Requirements as set out in AASB 1060: General Purpose Financial Statements – Simplified Disclosures for For-Profit and Not for Profit Tier 2 Entities. This application was approved by the Board of CCNSW.

CCNSW is a not-for-profit organisation and as such the term 'profit' is not applicable and the term 'surplus' is used where required.

Historical cost convention

These financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and liabilities, certain classes of property, plant and equipment, and investment property.

(b) Change in accounting policy

CCNSW has adopted all of the new, revised or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) that are mandatory for the current reporting period. The adoption of these standards and interpretations did not have any significant impact on the financial performance of CCNSW.

During the year, the Board and management of CCNSW have elected to recognise volunteer services from 1 July 2022 in line with the policy option presented in AASB 1058 (*Income of Not-for-Profit*) as either donations-in-kind income or other form of contribution received, if the fair value of these can be reliably measured. The intent of this change in accounting policy is to provide additional disclosures on the nature and value of in-kind donations received by the organisation to achieve its strategic goals.

Volunteer services to be recognised as income or other form of contribution generally relate to pro bono services provided by professional services firms as the fair value of these services can be reliably measured. However, volunteer services provided by members of the public in their individual capacity (including the Directors of the Board) are not recognised in the financial statements as the fair value cannot be measured reliably.

This application is applied prospectively; as such, no retrospective adjustments have been made to the opening equity balances as at 1 July 2022 as the volunteer services received in the prior year cannot be measured reliably and have nil impact on the financial statements (all volunteer services received in the prior year were consumed and expensed within that year).

Refer to Note 4 for additional disclosures.

(c) Income tax

CCNSW is exempt from income tax within the terms of Subdivision 50-5 of the *Income Tax Assessment Act 1997* (Cth).

(d) Goods and services tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, unless the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). In this case, it is recognised as part of the cost of acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST receivable from or payable to the ATO is included with other receivables or payables in the statement of financial position.

(e) Public company limited by guarantee

In the event of CCNSW being wound up, the liability of each member is limited to an amount not exceeding \$2.

(f) Rounding off

CCNSW is of a kind referred to in Legislative Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to the 'rounding off' of amounts in the financial report. Amounts in the financial report have been rounded off in accordance with the class order to the nearest thousand dollars.

(g) Comparative figures

Where necessary, amounts relating to prior years have been reclassified to facilitate comparison and achieve consistency in disclosure with current year amounts.

(h) Critical estimates and judgements

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying CCNSW's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, can be found in the following notes to the financial statements:

	Note
Financial assets	9
Useful life of assets	11,12
Employee benefits	17

(i) Financial assets at fair value through profit or loss

CCNSW holds an investment in shares classified as financial assets at fair value through profit or loss. As at 1 July 2018, in adopting AASB 9: Financial Instruments, CCNSW has made an irrevocable election on initial recognition to present gains and losses on investments in equity instruments that are not held for trading through profit or loss.

(ii) Estimation of useful lives of assets

CCNSW determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment, and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or where technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

(iii) Long service leave provision

The liability for long service leave is recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

(iv) Determining whether a grant contains enforceable and sufficiently specific obligations

The interaction between AASB 15 and AASB 1058 requires management to assess whether the government grants and other funding received need to be accounted for under AASB 15 or AASB 1058. Key to this assessment is whether the government funding and other funding agreements contain:

- a contract with a customer that creates 'enforceable' rights and obligations, and
- the contract includes 'sufficiently specific' performance obligations.

Critical judgement was applied by management in assessing whether a promise is 'sufficiently specific'. This took into account all facts and circumstances and any conditions specified in the arrangement (whether explicit or implicit) regarding the promised goods or services, including conditions regarding:

- the nature or type of the goods and services
- the cost or value of the goods and services
- the quantity of the goods and services, and
- the period over which the goods and services must be transferred.

3. Fundraising

	2023 \$'000	2022 \$'000
(a) Fundraising income		
Gifts in wills	18,703	14,035
Regular giving, appeals and donations	18,736	18,137
Campaigns	17,112	13,193
Philanthropy*	11,635	8,396
	66,186	53,761
Fundraising revenue is recognised under AASB 1058 when received or receivable.		
*Philanthropy income includes donated items auctioned at fundraising events and valued at the auction price. Total auction proceeds for the year are \$259,449 (2022: \$238,780).		
(b) Fundraising activities		
The below information is furnished under the <i>Charitable Fundraising Act 1991</i> (NSW) and NSW Fair Trading Fundraising Authority Conditions.		
Gross proceeds from fundraising activities (including gifts in wills)	66,186	53,761
Total cost of fundraising appeals	(27,689)	(23,144)
Net surplus from fundraising appeals	38,497	30,617
(c) Mission expenditure		
Research	18,172	18,240
Cancer information and support services	16,357	15,285
Sale of sun protection products (retail)	5,826	5,044
Advocacy and cancer prevention	10,173	8,374
Direct mission support - Marketing and communications*	2,310	2,363
Total mission expenditure**	52,838	49,306
Mission spend as a percentage of total expenses	62%	66%
Mission spend as a percentage of net surplus from fundraising	137%	161%

*Items from these categories which are directly related to mission have been reallocated to direct mission support.

**Total mission expenditure excludes donation-in-kind expenses

4. Revenue and other income

	2023 \$'000	2022 \$'000
Revenue and other income		
Sale of Retail Products recognised at a point in time	6,654	5,191
Provision of services rendered at a point in time (other income)	1,410	1,034
Non-government grants recognised at a point in time	2,098	2,353
Government Grants recognised at a point in time:		
NSW Department of Communities and Justice	-	143
Cancer Institute NSW	259	248
Australian Government, National Health and Medical Research Council	1,024	648
Australian Government, Department of Health	1,006	666
Australian Government, Department of Industry, Science, Energy and Resources	28	-
Australian Government, Cancer Australia	10	-
	12,489	10,283
Non-government grants recognised over time	182	397
Government Grants recognised over time:		
Australian Dept. Industry, Science, Energy and Resources	-	70
Australian Government Department of Health	1,474	1,447
Cancer Institute NSW	483	347
NSW Ministry of Health	-	105
	14,628	12,649
Donations-in-kind income*	2,134	-
Fundraising	66,186	53,761
NSW Government - Job Saver	-	400
Interest and Investment	6,964	11,036
Total revenue and other income	89,912	77,846

*Donations-in-kind income include:

- donated goods measured at fair value amounting to \$296,376 (2022: \$Nil), and
- volunteer services measured at fair value amounting \$1.84 million (2022: \$Nil).

Donations in-kind income of \$1.89 million has been expensed during the year as and when the benefit has been consumed, while the remaining income of \$242,500 relating to donated office furniture items has been capitalised (refer to Note 11).

Volunteer services

Volunteer services are recognised if the fair value can be reliably measured. Income from volunteer services is immediately expensed once the services have been utilised. No retrospective adjustments have been applied as the fair value cannot be measured reliably for the prior year.

Volunteer services recognised as income generally relate to pro bono services provided by professional services firms as the fair value of these services can be reliably measured. However, volunteer services provided by members of the public in their individual capacity (including the Directors of the Board) are not recognised in the financial statements as the fair value cannot be measured reliably.

5. Grants and government support received

	Opening balance 1 July 2022 \$'000	Income recognised during the year \$'000	Payments during the year \$'000	Closing balance 30 June 2023 \$'000
Cancer research grants	2,544	4,909	(4,717)	2,736
Community support grants	225	516	(637)	104
Cancer prevention grants	813	1,139	(1,328)	624
Total grants	3,582	6,564	(6,682)	3,464

Grants from the government and other organisations are recognised at their fair value through profit and loss where the sufficiently specific performance obligations of the grant have been met. Where those obligations have not been met for the year, revenue is deferred until those obligations are satisfied.

Where a grant is received without sufficiently specific performance obligations the revenue is recognised upon receipt through profit and loss.

6. Research expenditure

	2023 \$'000	2022 \$'000
Research	18,172	18,239
	18,172	18,239

As at 30 June 2023 Cancer Council has recognised all grant commitments on the Statement of Financial Position. These liabilities have been split as per accounting guidelines between their current and non-current portions.

7. Trade and other receivables

	2023 \$'000	2022 \$'000
Trade receivables	3,513	8,066
Provision for impairment of trade receivables	(2)	(2)
NSW share of donations and bequests due from Cancer Council Australia	4,570	2,488
Other receivables	1,344	1,099
	9,425	11,651

Trade receivables are initially recognised at fair value, and subsequently measured at amortised cost. Trade receivables are generally due for settlement within 30 days.

A provision is made for doubtful debts when there is evidence that those debts may not be collected. Bad debts are written off when identified.

8. Cash and cash equivalents

	2023 \$'000	2022 \$'000
Cash on hand and at bank	7,547	8,632
Term deposits with maturity less than 3 months	4,500	-
	12,047	8,632

For statement of cash flow presentation purposes, cash and cash equivalents include cash on hand; deposits held at call with financial institutions; and other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and that are subject to an insignificant risk of change in values.

9. Financial assets

	2023 \$'000	2022 \$'000
Current assets – Financial assets at amortised cost		
Term deposits	12,205	21,000
Bank guarantees	219	218
	12,424	21,218
Non-current assets – Investments at fair value through profit or loss		
(a) Investments at the end of the financial year were as follows:		
Australian shares	37,164	32,565
International Shares	22,821	18,953
Real assets	3,837	3,883
Fixed interest	19,883	15,886
Cash fund	4,696	8,483
	88,401	79,770
Changes in the fair value of investments are recorded in equity and disclosed through profit or loss.		
(b) Movement in investments		
Opening balance 1 July	79,770	85,576
Additions	72,931	13,356
Increase/(decrease) in fair value of managed funds	34	(15,162)
Disposals	(64,334)	(4,000)
Closing balance 30 June	88,401	79,770

Classification of financial assets

CCNSW classifies its financial assets in the following categories: 'investments at fair value through profit or loss', and 'financial assets at amortised cost'. The classification depends on the purpose for which the financial assets were acquired. Management determines the classification of CCNSW's financial assets at initial recognition:

(i) Investments at fair value through profit or loss
Initial recognition

CCNSW may make an irrevocable election (on an instrument-by-instrument basis) to recognise the change in fair value of investments through profit or loss and disclosed in the investments at fair value reserve. Investments are carried at fair value through profit or loss and transaction costs are immediately expensed.

Subsequent measurement

Subsequent to initial recognition, investments are measured at fair value and changes therein are recognised through profit or loss and disclosed in the investments at fair value reserve.

Distributions received from these investments are recognised in profit or loss as part of interest and investment income.

Derecognition

Investments are derecognised when the rights to receive cash flows from the investments have expired or have been transferred, and CCNSW has transferred substantially all the risks and rewards of ownership.

At the time of derecognition, redemption or sales of investments are at fair values on the trade date with fair value gain or loss leading up to the trade date for the year recognised in profit or loss. If the consideration received from derecognition of the investment is more or less than its fair value, the difference is recognised as gain or loss on derecognition in the profit or loss.

When investment is derecognised, the cumulative gain or loss is transferred directly from investments at fair value reserve to accumulated surplus and is not recognised in profit or loss (the net impact on equity is nil as the cumulative gain or loss is reclassified within equity).

(ii) Other financial assets at amortised cost
Initial recognition and subsequent measurement

Other financial assets at amortised cost are recognised initially at fair value and subsequently measured at amortised cost using the effective interest rate method, less provision for impairment.

Interest income from these financial assets is recognised in profit or loss as part of interest and investment income.

Derecognition

Other financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred, and CCNSW has transferred substantially all the risks and rewards of ownership.

10. Contract liabilities

	2023 \$'000	2022 \$'000
Contract liabilities	2,537	3,878
	2,537	3,878

Contract liabilities represent CCNSW's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when CCNSW recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before CCNSW has transferred the goods or services to the customer.

11. Property, plant and equipment

	Buildings* \$'000	Freehold land* \$'000	Motor vehicles \$'000	Office furniture and equipment \$'000	Leasehold improvements \$'000	Total \$'000
Year ended 30 June 2023						
Opening net book amount	28,364	20,500	607	843	283	50,597
Additions**	-	-	112	860	-	972
Depreciation expense	(804)	-	(275)	(363)	(83)	(1,525)
Closing net book amount	27,560	20,500	444	1,340	200	50,044
At 30 June 2023						
Cost or fair value	30,056	20,500	1,837	8,356	2,276	63,025
Accumulated depreciation	(2,496)	-	(1,393)	(7,016)	(2,076)	(12,981)
Net book amount	27,560	20,500	444	1,340	200	50,044

*Valued at Fair Value

**Additions to Office, furniture and equipment include donated office furniture items amounting to \$242,500

Valuations of freehold land and buildings

All property, plant and equipment categories are valued at cost, with the exception of land and buildings. The valuation basis of land and buildings is fair value and is carried out every three years. Building valuations were conducted as at 30 June 2021, with revaluations based on independent assessments by members of the Australian Property Institute. The revaluation increment was credited to the asset revaluation reserve in accumulated funds. The next valuation will be carried out as at 30 June 2024.

Any accumulated depreciation at the date of revaluation is eliminated against the gross carrying amount of the asset, and the net amount is restated to the revalued amount of the asset. All other property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Land is not depreciated. Depreciation on other assets is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives, as follows:

- buildings 25 to 40 years
- leasehold improvements 2 to 5 years
- office furniture and equipment 3 to 10 years
- motor vehicles 5 years

The asset residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount. Gains and losses are determined by comparing proceeds with carrying amount. These are included in the statement of profit or loss.

12. Intangible assets

	Computer software \$'000	Internally generated software assets \$'000	Total \$'000
Year ended 30 June 2023			
Opening net book amount	41	5,406	5,447
Additions	-	570	570
Write-off to expense*	-	(339)	(339)
Impairment loss recognition**	-	(1,430)	(1,430)
Amortisation	(15)	(1,604)	(1,619)
Closing net book amount	26	2,603	2,629
At 30 June 2022			
Cost	1,029	12,352	13,381
Accumulated amortisation	(1,003)	(6,954)	(7,957)
Intangible impairment	-	(2,795)	(2,795)
Net book amount	26	2,603	2,629

*Configuration and customisation costs incurred in the prior year for Software as a Service (SaaS) related arrangements have been expensed to statement of profit or loss in line with the guidelines issued by the IFRS Interpretations Committee (IFRIC).

**During the year, CCNSW management carried out impairment testing of its internally generated software assets. Management have assessed the book value of the business transformation project capitalised between 2015 to 2018 to have exceeded its recoverable value (value-in-use) due to technological obsolescence resulting from implementation of improved alternative software during the year.

As such, the total book value of \$1.4 million for the business transformation project has been reduced to nil, resulting in recognition of \$1.4 million impairment loss for the year ended 30 June 2023.

Finite intangible assets include acquired or developed software, capitalised on the basis of the costs incurred to acquire and install the software. Subsequent software expenditure is expensed as incurred.

Finite intangible assets are accounted for using the cost model, whereby capitalised costs are amortised on a straight-line basis over their estimated useful lives (between 3 to 10 years). Residual values and useful lives are reviewed at each reporting date.

CCNSW continues to invest in technology to improve how it engages with the community, simplify its working environment and help it work more effectively.

At financial year-end, intangibles were reviewed with the above impairment calculated as the expended cost on software development no longer having future benefit to CCNSW.

13. Right of use assets

	2023 \$'000	2022 \$'000
Opening balance 1 July	1,194	1,712
Additions	581	548
Less: accumulated depreciation	(878)	(1,066)
Closing balance 30 June	897	1,194

Included in surplus/(deficit) for the year are \$877,825 (2022: \$1,065,715) of depreciation of right-of-use assets and \$39,240 (2022: \$50,202) of finance cost on lease liabilities. Expenses relating to short-term leases included in administrative expense in the profit or loss for the period were \$545,240 (2022: \$274,011). The total cash outflow for leases for the year was \$966,685 (2022: \$1,104,815).

14. Trade and other payables

	2023 \$'000	2022 \$'000
Trade creditors and accruals	2,543	6,766
Cancer Council Australia membership fees	1,912	1,630
Other current payables	515	241
	4,970	8,637

These amounts represent liabilities for goods and services provided to CCNSW prior to the end of the financial year and that were unpaid as at the reporting date. These amounts are unsecured and are paid within the suppliers' terms, usually 30 days.

15. Provision for grants

	2023 \$'000	2022 \$'000
Current grant provision	7,094	7,374
Non-current grant provision	5,925	7,446
Total grant liability	13,019	14,820

A provision is recognised when Cancer Council NSW has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and the amount can be reliably measured.

Liabilities relating to research grants are provided for in order to recognise Cancer Council's obligation to pay grants to external agencies in accordance with funding agreements that commit Cancer Council NSW to pay these funds per agreed milestones.

16. Lease liabilities

	2023 \$'000	2022 \$'000
Current lease liability	412	929
Non-current lease liability	488	318
Total lease liability	900	1,247

The above lease liabilities represent the present value of the remaining lease payments, discounted using the appropriate incremental borrowing rate.

Future lease payments

Future lease payments are due as follows:

Within one year	412	929
One to five years	488	318
	900	1,247

17. Employee benefits

	2023 \$'000	2022 \$'000
(a) Employee benefits provisions – Current		
Annual leave	2,776	2,996
Long service leave	1,358	1,067
Current employee benefits	4,134	4,063
(b) Employee benefits provisions – Non-current		
Long service leave	919	1,055
Non-current employee benefits	919	1,055

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, and leave expected to be settled within 12 months of the reporting date, are recognised in current liabilities, and are measured at the amounts expected to be paid when the liabilities are settled.

Other long-term employee benefits

Leave liabilities not expected to be settled within 12 months of the reporting date are recognised in non-current liabilities. The liability is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date, using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures, and periods of service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

(c) Employee benefits expense		
Employee benefits expense	39,204	39,134

18. Key management personnel

	2023 \$	2022 \$
(a) Executive remuneration		
Executive (excluding Directors of the Board) remuneration expense	2,190,836	2,316,432

Directors of the Board are all volunteers, and receive no remuneration for their services.

(b) Transactions with Directors and key management personnel

During the financial year Dr John Laker and Dr Jo Mitchell were unpaid Board members of both CCNSW and Cancer Council Australia (CCA). Total membership fees expense the year charged to CCNSW by CCA is \$2,317,419 (2022: \$1,975,052).

As at 30 June 2023:

- CCNSW owed CCA \$1,911,870 for membership fees (2022: \$1,629,418) disclosed in trade and other payables (Note 14).
- CCNSW was due to receive distributions from CCA for the NSW share of donations and bequests of \$4,569,669 (2022: \$2,488,067) disclosed in trade and other receivables (Note 7).

19. Remuneration of auditors

	2023 \$	2022 \$
Audit of the Financial Statements	68,000	65,000

20. Contingent liabilities

Contingent liabilities

CCNSW had no contingent liabilities as at 30 June 2023.

Bank Guarantees

CCNSW had provided the following guarantees as at 30 June 2023:

- bank guarantees in respect of property operating leases amounting to \$219,326 (2022: \$218,000).

21. Events after reporting period

CCNSW was not aware of any events that have occurred after reporting date that are of such significance that they need to be disclosed or recognised in the financial statements.

22. Interests in joint ventures

CCNSW has entered into a joint venture to provide accommodation for cancer patients and their relatives while receiving radiotherapy treatment in NSW: Lilier Lodge at Wagga Wagga.

CCNSW holds a 50% voting power in Lilier Lodge.

CCNSW holds a 50% ownership interest in the operations of Lilier Lodge and is entitled to a 50% share of its output.

CCNSW's 50% interest in Lilier Lodge's assets, liabilities, revenues and expenses was recognised in the financial statements as part of a joint operation.

23. New or amended Accounting Standards and Interpretations adopted

CCNSW has adopted all of the new, revised or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) that are mandatory for the current reporting period. The adoption of these standards and interpretations did not have any significant impact on the financial performance of CCNSW.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

END OF AUDITED FINANCIAL STATEMENTS

Directors' declaration

In the Directors' opinion:

- the attached financial statements and notes thereto comply with the Australian Charities and Not-for-profits Commission Act 2012 (Cth), Australian Accounting Standards – Simplified Disclosure Requirements, the Australian Charities and Not-for-profits Commission Regulations 2013 and other mandatory professional reporting requirements
- the attached financial statements and notes thereto give a true and fair view of the company's financial position as at 30 June 2023 and of its performance for the financial year ended on that date, and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the Directors by:



Dr John Laker AO
Director

Sydney
24 October 2023



Michael Morgan
Director

Sydney
24 October 2023

Declaration by Chief Executive Officer in respect of fundraising appeals

I, Sarah Hosking, Chief Executive Officer of The Cancer Council NSW declare that in my opinion:

- a) the income statement gives a true and fair view of all income and expenditure of The Cancer Council NSW with respect to fundraising appeals
- b) the balance sheet gives a true and fair view of the state of affairs with respect to fundraising appeals
- c) the provisions of the Charitable Fundraising Act 1991 (NSW), the regulations under the Act and the conditions attached to the authority have been complied with, and
- d) the internal controls exercised by The Cancer Council NSW are appropriate and effective in accounting for all income received and applied by The Cancer Council NSW from any of its fundraising appeals.



Professor Sarah Hosking
Chief Executive Officer

Sydney
24 October 2023

INDEPENDENT AUDITOR'S REPORT

To the members of The Cancer Council NSW

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of The Cancer Council NSW (the registered entity), which comprises the statement of financial position as at 30 June 2023, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the responsible entities' declaration.

In our opinion the accompanying financial report of The Cancer Council NSW, is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) Giving a true and fair view of the registered entity's financial position as at 30 June 2023 and of its financial performance for the year then ended; and
- (ii) Complying with Australian Accounting Standards – Simplified Disclosures and Division 60 of the *Australian Charities and Not-for-profits Commission Regulations 2022*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The responsible entities of the registered entity are responsible for the other information. The other information obtained at the date of this auditor's report is information included in the registered entity's annual report, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of responsible entities for the Financial Report

The responsible entities of the registered entity are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards – Simplified Disclosures and the ACNC Act, and for such internal control as the responsible entities determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, responsible entities are responsible for assessing the registered entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intends to liquidate the registered entity or to cease operations, or has no realistic alternative but to do so.

The responsible entities of the registered entity are responsible for overseeing the registered entity's financial reporting process.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf

This description forms part of our auditor's report.

BDO Audit Pty Ltd



Leah Russell

Director

Sydney, 26 October 2023

Contact us.

153 Dowling Street
Woolloomooloo NSW 2011
feedback@nswcc.org.au

 facebook.com/cancercouncilnsw

 [@ccnewsouthwales](https://twitter.com/ccnewsouthwales)

 youtube.com/cancercouncilnsw

 [@cancercouncilnsw](https://instagram.com/cancercouncilnsw)

 linkedin.com/company/cancer-council-nsw

13 11 20 cancercouncil.com.au



**Cancer
Council**
NSW